CA2728562C - Methods for treating multiple sclerosis using antisense oligonucleotides - Google Patents

Methods for treating multiple sclerosis using antisense oligonucleotides Download PDF

Info

Publication number
CA2728562C
CA2728562C CA2728562A CA2728562A CA2728562C CA 2728562 C CA2728562 C CA 2728562C CA 2728562 A CA2728562 A CA 2728562A CA 2728562 A CA2728562 A CA 2728562A CA 2728562 C CA2728562 C CA 2728562C
Authority
CA
Canada
Prior art keywords
multiple sclerosis
methods
antisense oligonucleotides
treating multiple
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2728562A
Other languages
English (en)
French (fr)
Other versions
CA2728562A1 (en
Inventor
Ety Klinger
Shoshi Tessler
Hussein Hallak
George Tachas
Mark Paul Diamond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Percheron Therapeutics Ltd
Original Assignee
Antisense Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antisense Therapeutics Ltd filed Critical Antisense Therapeutics Ltd
Publication of CA2728562A1 publication Critical patent/CA2728562A1/en
Application granted granted Critical
Publication of CA2728562C publication Critical patent/CA2728562C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2728562A 2008-06-23 2009-06-23 Methods for treating multiple sclerosis using antisense oligonucleotides Active CA2728562C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13297308P 2008-06-23 2008-06-23
US61/132,973 2008-06-23
PCT/US2009/003760 WO2010008474A2 (en) 2008-06-23 2009-06-23 Methods for treating multiple sclerosis using antisense oligonucleotides

Publications (2)

Publication Number Publication Date
CA2728562A1 CA2728562A1 (en) 2010-01-21
CA2728562C true CA2728562C (en) 2018-10-23

Family

ID=41550900

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2728562A Active CA2728562C (en) 2008-06-23 2009-06-23 Methods for treating multiple sclerosis using antisense oligonucleotides

Country Status (8)

Country Link
US (2) US8415314B2 (enExample)
EP (2) EP2318424B1 (enExample)
JP (2) JP5988581B2 (enExample)
AU (1) AU2009271678B2 (enExample)
CA (1) CA2728562C (enExample)
DK (2) DK2937358T3 (enExample)
ES (2) ES2699891T3 (enExample)
WO (1) WO2010008474A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2728562C (en) 2008-06-23 2018-10-23 Ety Klinger Methods for treating multiple sclerosis using antisense oligonucleotides
CA2811228C (en) * 2010-09-17 2023-03-14 Antisense Therapeutics Ltd Method for reducing circulating leukocytes in a human subject
US10376536B2 (en) 2015-05-11 2019-08-13 Murdoch University Multiple sclerosis treatment
US11891606B2 (en) * 2017-06-16 2024-02-06 Antisense Therapeutics Ltd Methods for treating multiple sclerosis using antisense oligonucleotides
JP7604361B2 (ja) * 2018-05-04 2024-12-23 アンチセンス セラピューティクス リミテッド 治療での使用及び方法
KR20220061915A (ko) * 2019-05-06 2022-05-13 안티센스 테라퓨틱스 엘티디 Cd49d에 대한 억제성 올리고뉴클레오티드를 사용하는 근이영양증의 치료 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242591B1 (en) * 1997-10-15 2001-06-05 Isis Pharmaceuticals, Inc. Synthesis of sulfurized 2'-substituted oligonucleotides
US5968826A (en) * 1998-10-05 1999-10-19 Isis Pharmaceuticals Inc. Antisense inhibition of integrin α4 expression
US20070237717A1 (en) * 2004-04-05 2007-10-11 Roland Martin Methods for Selection of Subjects for Multiple Sclerosis Therapy
JP2008516991A (ja) * 2004-10-20 2008-05-22 アンチセンス セラピューティクス リミテッド インテグリンα４発現のアンチセンス調節
CA2728562C (en) 2008-06-23 2018-10-23 Ety Klinger Methods for treating multiple sclerosis using antisense oligonucleotides

Also Published As

Publication number Publication date
EP2937358A1 (en) 2015-10-28
JP6131230B2 (ja) 2017-05-17
JP5988581B2 (ja) 2016-09-07
ES2699891T3 (es) 2019-02-13
DK2318424T3 (en) 2015-04-07
EP2318424A2 (en) 2011-05-11
EP2318424A4 (en) 2012-12-26
WO2010008474A3 (en) 2010-04-22
JP2015044824A (ja) 2015-03-12
CA2728562A1 (en) 2010-01-21
AU2009271678B2 (en) 2013-09-19
WO2010008474A4 (en) 2011-01-27
ES2532404T3 (es) 2015-03-26
US20100119480A1 (en) 2010-05-13
US20130345293A1 (en) 2013-12-26
AU2009271678A1 (en) 2010-01-21
WO2010008474A2 (en) 2010-01-21
DK2937358T3 (da) 2019-01-02
EP2937358B1 (en) 2018-09-19
US8759314B2 (en) 2014-06-24
JP2011525531A (ja) 2011-09-22
US8415314B2 (en) 2013-04-09
EP2318424B1 (en) 2015-02-25

Similar Documents

Publication Publication Date Title
MA31027B1 (fr) INHIBITEURS DE L'ACTIVITE Akt
EP2255798A3 (en) Sphingosine-1-phosphate receptor agonists for use in the treatment of optic neuritis
MX2009013699A (es) Aplicador de una composicion para el tratamiento del cabello.
MA30296B1 (fr) Nouvelles amines
MX2010002258A (es) Compuestos terapeuticos de isoxazol.
MX2019012750A (es) Moduladores del receptor s1p para el tratamiento de esclerosis multiple.
TW200744586A (en) Therapeutic compounds
MX2013009191A (es) Oligonucleotidos antisentido.
WO2010053861A3 (en) Biologically active amides
PL1948155T3 (pl) Kompozycje farmaceutyczne zawierające droksidopę
WO2007092190A3 (en) Methods and compositions for modulating sphingosine-1-phosphate (s1p) receptor activity
WO2009045356A8 (en) Microrna compositions in the treatment of vegf-mediated disorders
WO2007098099A3 (en) Method of treating a subject suffering from degenerative disc disease using a matrix metalloprotease inhibitor
MX2009005649A (es) Tratamiento para mieloma multiple.
MA29554B1 (fr) Nouveaux derives d'amide d'acide piperidine carboxylique
WO2010008474A3 (en) Methods for treating multiple sclerosis using antisense oligonucleotides
MA30292B1 (fr) Amines primaires comme inhibiteurs de la renine
WO2008079727A3 (en) Compositions comprising an pan-alpha-2 receptor agonist and an anticonvulsant for treating chronic pain
TN2010000108A1 (fr) Traitement de symtomes vasomoteurs
EP4424379A3 (en) Small molecule bromodomain inhibitors and uses thereof
EP2307006A4 (en) PHARMACEUTICAL COMPOSITION WITH A 1,2-DITHIOLTHION DERIVATIVE FOR THE PREVENTION OR TREATMENT OF A DISEASE ARISING FROM LXR-ALPHA OVEREXPRESSION
WO2004092379A3 (en) Method for treatment of angiogenic disorders
FR2909279B1 (fr) Procede de peeling a base de microgel cationique
DE602005020113D1 (de) Verfahren zur behandlung von akuten rhinosinusitis
WO2008039984A3 (en) Methods and compositions for treating conditions by inhibiting cathepsin d

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140611

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20241227